LONDON, Aug. 29, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland.
The Company will be showcasing its portfolio of immune profiling products for research use at Booth C13, and management will be available for discussions with research organizations and potential customers.
The European Congress of Immunology is the triennial joint meeting of all European Federation of Immunological Societies (EFIS). It is now one of the most highly regarded international conferences in the field of basic and clinical immunology, attracting on average more than 3,000 delegates and offering the highest standards in terms of both scientific and social programs. The theme for this year's congress is 'Conquering challenges with Immunology'.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson and Adanna G. Alexander, Ph.D.
M: 303-482-6405
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.56 |
| Daily Change: | -0.14 -8.24 |
| Daily Volume: | 210,888 |
| Market Cap: | US$6.770M |
September 09, 2024 August 23, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
